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 Cancer is a heavily studied, multifactorial disease with an incidence of nearly 1.7 
million in the U.S. alone. In a clinical study, a supportive social environment was shown 
to improve outcomes for breast cancer patients. Yet, animal model experiments have 
mainly focused on the negative effects of distress or social isolation on cancer outcomes. 
Our model of social enrichment, an enriched environment (EE), is a model of eustress, 
and we uniquely study the positive effects of the social environment on cancer outcomes. 
We have previously shown that EE exerts an anticancer effect. Here, we show that CD8 
T-cells are required for this effect. Furthermore, we show a shift to CD8 T-cells in 
secondary lymphoid tissue that is mediated by a molecule in the hypothalamus, brain-
derived neurotrophic factor. We also show a shift in thymocyte development toward CD8 
T-cells in EE that is regulated by the same molecule. We have further studied the 
complex effect of EE on the adipose tissue microenvironment, specifically on natural-
killer cells. Here, we show that adipose tissue-specific IL-15 overexpression results in 
increased NK cells in adipose tissue as well as increased NK cells at a nearby tumor and 
decreased mass of the nearby tumor. Finally, we extend the current knowledge of EE’s 
anticancer effect to a blood cancer, acute myeloid leukemia, in which we see a substantial 
increase in progression-free survival but a modest, yet still significant, increase in overall 
survival. These results together show the complex connection between the environment, 
the nervous system, the immune system, and the cancer microenvironment in mice. The 
continual regulation of EE’s anticancer effect by brain-derived neurotrophic factor 
suggests the possibility of manipulating a single gene in the brain for beneficial outcomes 
in certain cancers. Our model shows the importance of studying the positive effects of the 
















In our collaboration with the Cao lab, we have shown an anticancer effect in an 
enriched environment model of mice, an environment that is physically, cognitively, and 
socially stimulating. In studying this effect, we seek to find the pathways that connect the 
macroenvironment, namely an enriched environment, to the tumor microenvironment and 
by which an enriched environment confers its anticancer effect. In this collaboration, we 
have extensively studied this connection, identifying hypothalamic brain-derived 
neurotrophic factor as a key mediator of this anticancer effect.  
Here, I report our findings on T-cells in the thymus and the periphery, changes 
that create a T-cell repertoire that is more readily poised to lyse cancer cells. 
Furthermore, I report our initial findings on the role of natural killer cells in nearby 
adipose tissue in monitoring neighboring tumors. Finally, I report our preliminary results 
on EE’s beneficial effects on the progression of acute myeloid leukemia. Together, these 
results show a model for macroenvronmental stress, in the form of eustress, in the context 
of cancer. The pervasive control of hypothalamic brain-derived neurotrophic factor in 
controlling the immune changes associated with an enriched environment’s anticancer 
effect suggest the possibility of manipulating a single gene in the brain for beneficial 




Our collaboration with the Cao lab has produced a large amount of data, only 
some of which is presented here. I have chosen to report the data that most clearly relate 
to cancer, as this is the research and specialty I have always found most interesting and I 
am most likely to pursue. With that being said, some of the experiments presented here 
were designed after substantial investigation into adipose tissue in the enriched 
environment, a topic that I do not include here. I have included a brief background of 
these experiments in order to explain the rationale for these experiments. 
Finally, this work has been highly collaborative. This work is a result of thorough 
work on the part of my mentor, Stephen Bergin, our direct collaborator in the Cao lab, 
Run Xiao, and myself, as well as many others in both of our labs. While I have 
contributed to the entire scientific process of these experiments, this work is not my work 
alone. Specifically, I have been a part of the mouse sacrifice, tissue processing, 
preparation and sample running on flow cytometry, data analysis of flow cytometry, and 
figure creation. Molecular work, such as polymerase chain reaction (PCR) and vector 
creation, as well as vector injection into the hypothalamus was completed by our 












 Stress has long been known as a key mediator of disease onset and progression1,2. 
Distress has been studied frequently in the context of both obesity and cancer. With 
obesity, stress is a concomitant risk factor for hypertension and metabolic diseases3. 
Furthermore, obesity has been theorized as an adaptive response to chronic stress4.  
Specific to cancer, distress is hypothesized to affect the progression of cancer. A patient’s 
subjective sense of stress concerning their cancer diagnosis is predictive of a weakened 
immune system5. In a clinical study of breast cancer, stress was correlated with incidence 
of cancer, and a more supportive social environment has been linked with improved 
outcomes6.  
Traditionally, there are two stress axes: the sympathetic nervous system and the 
hypothalamic-pituitary-adrenal axis. The sympathetic nervous system (SNS) is the 
component of the autonomic nervous system that is typically referred to as the “fight-or-
flight” response. Activation of SNS results in release of stress hormones from the adrenal 
medulla, preferential use of glycolysis for energy, and decreased immune function. The 
hypothalamic-pituitary-adrenal (HPA) axis, on the other hand, is an endocrine response 
to stress. The release of corticotropin releasing hormone (CRH) from the hypothalamus 
into the blood triggers release of adrenocorticotropic releasing hormone (ACTH) from 
the anterior pituitary. ACTH then travels through the blood and causes the adrenal cortex 
to release glucocorticoids, another classic stress hormone. 
These stress pathways are classically studied in the context of distress. Eustress, 
as opposed to distress, is “positive stress” involving cognitive activation without the 
classic detrimental and exhaustive effects of distress7. The role of eustress is less 
understood on a molecular level8, even though clinical studies suggest a link with cancer 
outcomes6.  Our lab collaborates with the Lei Cao lab that has extensively studied the 
effect of an enriched environment (EE) in mice9,10,11. EE is physically, cognitively, and 
socially stimulating compared to standard environment (SE) housing, and as such can be 
used as an animal model of eustress. EE has previously been associated with an anti-
obesity effect and positive metabolic changes, which are not extensively discussed here.9 
The Cao lab previously showed that EE exerts an anticancer effect, through 
reduced tumor growth and increased remission, in models of melanoma and colon cancer. 
They also reported that hypothalamic brain-derived neurotrophic factor (BDNF) was 
upregulated in EE, independent of extra exercise. BDNF has previously been shown as an 
important, early molecule in brain development12. It is highly responsive to exercise and 
the environment and has been linked with satiation of appetite and energy 
homeostasis13,14. Furthermore, overexpression of BDNF in SE led to reduced tumor 
burden, and BDNF knockdown blocked the anticancer effect of EE9, leading to the 
conclusion that BDNF was at least partially responsible for EE’s anticancer phenotype. 
The immune and molecular mechanisms by which EE exerts its anticancer 
phenotype are previously unknown. We propose a peripheral and developmental model 
for T-cell control of EE’s anticancer phenotype. Additionally, we present a novel 
understanding of the relationship between the adipose immune microenvironment and 
local tumor proliferation. Finally, we show that EE has beneficial results in a blood 





(1) T-cell depletion experimental design 
(2) Confirmation of T-cell depletion 
(3) CD8 T-cells partially mediate EE’s anticancer effect 
(4) T-cell phenotype in SLT of EE 
(5) BDNF overexpression and depletion 
a. Confirmation of overexpression in hypothalamus 
b. T-cell phenotype in SLT reproduced in overexpression 
c. Confirmation of knockdown in hypothalamus 
d. T-cell phenotype in SLT eliminated in knockdown 
(6) SNS regulation of T-cell phenotype in SLT 
(7) HPA regulation of T-cell phenotype in SLT 
(8) Thymus development changes in EE 
a. Thymic involution 
b. Thymus phenotypes at one, four, and twelve weeks 
c. Representative flow images for thymus phenotype 
(9) Thymocyte retention in EE 
(10) BDNF regulation of thymus phenotype (overexpression) 
(11) BDNF regulation of thymus phenotype (depletion) 
(12) HPA regulation of thymus phenotype (adrenalectomy) 
(13) Binding of GC’s to developing T-cells (GR-LCK mice) 
(14) IL-15 overexpression 
a. Tumor photograph 
b. Tumor mass 
c. Immune changes 
(15) AML preliminary study 
a. Survival curve 
b. Immune changes at three weeks 
c. Immune changes at five weeks 
(16) Photograph of EE 




Statistical	  considerations:	  p-­‐values	  are	  represented	  by	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  significance	  









(1) T-cells in EE  
 
Cytotoxic T lymphocytes (CTLs) recognize and kill cancer cells. CD8 is the defining 
marker of CTLs, in contrast to CD4 T cells. T-cells develop in the thymus but migrate to 
and are stored in secondary lymphoid tissue (SLT), such as the lymph node (LN) and 
spleen, before exportation to the periphery. Therefore, we hypothesize that CD8 
cytotoxic T lymphocytes mediate the anticancer effect of EE. 
 
EE requires CD8 T-cells to mediate anticancer phenotype 
 
 To test whether CTLs were required to mediate EE’s anticancer phenotype, we 
administered CD8-depleting antibody or IgG antibody as control to mice in either EE or 
SE housing. Mice were housed in their respective cages for five weeks, which is the 
approximate amount of time when we have previously observed EE-associated metabolic 
changes. At this time, EE mice weighed less, positively confirming the metabolic effects 
of EE (data not shown). At that time, mice were injected with either CD8-depleting or 
IgG antibody. After 24 hours, mice were injected with a B16 melanoma cell line and 












 To confirm depletion of CD8 T-cells in the depletion group, we ran flow 
cytometry of blood. All mice in both depleting groups showed sufficient depletion of 
CD8 T-cells that did not deplete CD4 T-cells. A representative flow image is show in 












Figure	  3.	  CD8	  T-­‐cells	  partially	  mediate	  EE’s	  anticancer	  effect	  

















































































































































Within the IgG control group, EE tumors weighed significantly less (p<0.001) 
than SE, confirming our previous studies. Within the CD8-depleting antibody groups, 
there was no significant difference between EE and SE (p>0.07). Importantly between the 
EE groups, mice administered CD8-depleting antibody had significantly larger tumors 
than those administered IgG control, suggesting that CTLs play at least some role in 
mediating EE’s anticancer effect (Figure 3). 
 
 
EE shifts CD8 T cell populations  
 
 We next wanted to test whether EE affects T-cell populations in the periphery, 
such as in SLT, to support this anticancer effect. To do this, we measured the CD4:CD8 
ratio. A lower ratio, with a higher percentage of CD8 T-cells, represents a T-cell 
repertoire more readily poised to lyse cancer cells by detecting the down-regulation of 
MHC-I. Furthermore, we wanted to see whether this potential T-cell change preceded 
other immunological changes we had previously observed in macrophages and NK cells. 
 We housed mice in either EE or SE for one or four weeks. We sacrificed mice and 
analyzed SLT, specifically lymph node (LN) and spleen for T-cell populations using flow 
cytometry. (Gating strategies are described in methods.)  
At both one and four weeks, both LN and spleen showed a decreased CD4:CD8 
ratio (Figure 4A and 4B). Exposure to EE for only one week produced a distinct change 
in T-cell populations in SLT. The CD4:CD8 ratio does not continue to decrease with 
extended exposure to EE, indicating that EE induces a distinct T-cell balance that is 
consistently induced at an early time point. 
 
 
Figure	  4.	  T-­‐cell	  phenotype	  in	  SLT	  
A	   B	  
 
BDNF controls T-cell populations in EE 
 
 We have previously seen BDNF as a key regulator of EE’s metabolic effects on 
weight and obesity as well as tumor resistance. Therefore, we hypothesized that BDNF 
regulated the T-cell changes we had observed. To test this hypothesis, we carried out both 
an overexpression experiment and a depletion experiment. 
 To test whether overexpression of BDNF was sufficient to induce our observed T-
cell phenotype, we injected a recombinant adeno-associated virus (rAAV) vector 
containing BDNF or GFP as a control directly into the hypothalamus of mice that were 
maintained in SE housing. (rAAV-GFP is represented by the blue bar, and rAAV-BDNF 
is represented by the red bar.) Vector localization to the hypothalamus was confirmed by 
GFP fluorescence (data not shown). BDNF overexpression was confirmed by quantitative 













Mice administered rAAV-BDNF had a significantly lower CD4:CD8 ratio 
compared to rAAV-GFP (Figure 5B). This suggests that BDNF overexpression is 
sufficient to induce T-cell changes in SE and that BDNF controls this anticancer T-cell 















Furthermore, we then tested whether knockout of BDNF eliminated the T-cell 
changes in EE. To do so, we injected either microRNA targeting BDNF or a microRNA 
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Figure	  5A.	  BDNF	  Overexpression	  Confirmation	  
targeting a scrambled sequence that does not target any known genes directly into the 
hypothalamus of mice living in either EE or SE. We confirmed the knockdown of BDNF 














As expected, mice administered microRNA targeting a scrambled sequence living 
in EE showed a decrease compared to their SE counterparts, confirming the control. Mice 
administered microRNA targeting BDNF in EE did not show a statistically significant 
difference from SE counterparts (Figure 5D). These results show that depletion of BDNF 
eliminates EE’s anticancer effect. Together with the overexpression experiment, BDNF is 














SNS and HPA axes both control EE downstream of BDNF 
 
In our previous study, we showed that sympathetic nervous system (SNS) 
signaling was required for EE’s anticancer effect. Furthermore, we showed that 
hypothalamic-pituitary-adrenal (HPA) signaling is upregulated in EE. As SNS and HPA 
are two classic stress control systems, we investigated whether they play a role in 
regulating our T-cell phenotype downstream of BDNF in the hypothalamus.  
We used a non-specific beta-blocker (βB), propranolol, to investigate the role of 
SNS in the EE-induced changes in T-cell homeostasis in EE. Propanolol prevents the 
binding of epinephrine to beta-receptors on effector cells. 
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Figure	  5C.	  BDNF	  Depletion	  Confirmation	  
 We housed mice in either EE or SE and administered propranolol in the drinking 
water of half of the mice and regular drinking water as a control. Mice administered 
propranolol had no significant CD4:CD8 ratio change between EE and SE (Figure 6), 

















To investigate the role of HPA signaling, we used an antagonist of cortisol 
receptors, mifepristone. Mifepristone prevents the binding of cortisol to its receptor on 
effector cells. Similar to the previous experiment, mice were housed in EE or SE, and 
half of the mice in each group were administered mifepristone by oral injection, while the 
other half received an oral injection of vehicle control. Administration of mifepristone 















Intermediate Conclusion #1: Environmental and genetic activation of hypothalamic 





Figure	  6.	  SNS	  Regulation	  
Figure	  7.	  HPA	  Regulation	  
(2) EE induces changes to the thymus and T-cell development 
 
 The experiments outlined in (1) show the peripheral changes in T-cells that 
mediate an anticancer effect in EE, as well as the regulation of this immune change. But, 
the immune development that leads to this change was not investigated. The thymus is 
the primary organ of T-cell development, and it serves a vital role in maintaining immune 
homeostasis through this function.  
The thymus undergoes significant changes in response to stress and age, typically 
decreasing in size through a process called thymic involution. We have previously 
observed thymic involution in EE but have not studied the specific effects of involution 
on T-cell development or its regulation. T-cells undergo a standard developmental 
process, defined by the presence or absence of CD4 and CD8. T-cells develop from CD4-
CD8- double negative (DN) cells to double positive (DP) and to single positive (SP) CD4 
T-helper or CD8 CTLs.  
Therefore, we hypothesize that EE shifts thymocyte development in the 
thymus toward CD8 CTLs and that this development is regulated similarly by 
BDNF and the stress axes. 
 
EE alters thymus development and retains single-positive T-cells 
 
 To test the effect of EE on T-cell development in the thymus, we housed mice in 
either EE or SE for 6 days, 4 weeks, or 12 weeks. A six-day exposure to EE was 
sufficient to induce a significant decrease in thymus mass in EE compared to SE, and this 
difference in thymic mass persisted at both 4 and 12 weeks (Figure 8A). A decrease in 
thymus mass is termed thymic involution and is a consistent finding in EE. Thymic 
involution is typically studied in the context of distress (psychological stress, infection, 














Within the stages of T-cell development, at each time point, we saw a higher 
































































































Figure	  8B.	  EE	  Thymus	  Phenotype	  















































We further hypothesized that changes in thymus retention of SP T-cells may 
contribute to the SLT phenotypes reported in (1). To test this hypothesis, we obtained 
RAG2-GFP mice in which GFP is expressed in T-cells that have recently undergone T-
cell receptor (TCR) rearrangement. TCR rearrangement occurs in the DN T-cell stage 
and results in unique T-cell receptors on developing T-cells. RAG2 is a gene expressed 
during TCR rearrangement. RAG2-GFP mice have GFP inserted into the open reading 
frame of the RAG2 gene such that whenever RAG2 is expressed, GFP is expressed. 
Thus, T-cells that have recently left the thymus can be detected as expressing GFP. 
RAG2/GFP mice were placed in SE or EE for 2 weeks. In SLT, we observed a 
significantly reduced CD4/CD8 ratio of GFP+ T-cells but no change when gated on GFP- 
T-cells (Figure 9A). Consistent with our hypothesis that EE housing preferentially retains 
CD4 T-cells, GFP expression was reduced in CD4 but not CD8 T-cells (Figure 8B). 
Overall, the data demonstrate that EE housing rapidly alters thymocyte development and 

































Figure	  9A.	  Thymocyte	  Retention	  
Figure	  9B.	  
BDNF controls EE’s thymus developmental changes 
 
 The experiments in (1) show BDNF control of T-cells in SLT, so we hypothesized 
that BDNF controls EE’s change in T-cell development in the thymus. Similar to (1), we 
used both an overexpression and a depletion model of BDNF.  
To test whether overexpression of BDNF was sufficient to induce our observed 
thymic development change, we injected a recombinant adeno-associated virus (rAAV) 
vector containing BDNF or GFP as a control directly into the hypothalamus of mice that 
were maintained in SE housing. (rAAV-GFP is represented by the blue bar, and rAAV-
BDNF is represented by the red bar.) Overexpression was similarly confirmed using 
quantitative RT-PCR (data not shown). 
Mice administered rAAV-BDNF significantly smaller thymuses than control 
(Figure 10A). Furthermore, within thymocyte populations, there was a reduction in DP 
cells and an increase in SP CD8 cells, as was observed in EE at several timepoints 





















Furthermore, we tested whether knockout of BDNF eliminated the changes in 
thymocyte development. To do this, we injected either microRNA targeting BDNF or a 




















































in either EE or SE. BDNF knockdown was similarly confirmed using quantitative RT-
PCR (data now shown). 
Comparing the two groups injected with microRNA targeting BDNF, we 
observed an increase in thymus weight in EE (Figure 11A). We also observed an increase 
in DP cells and a decrease in SP CD8 cells (Figure 11B and 11C). These results in the 
knockdown experiment actually represent a reversal of the results seen in EE in Figure 
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HPA signaling mediates EE immune phenotypes in SLT 
 
 As shown in (1), blockade of the HPA axis disrupted the T-cell changes in SLT. 
So we hypothesized that HPA may affect thymocyte development leading to these 
changes. In the HPA axis, corticotropin-releasing hormone (CRH) stimulates secretion of 
aderenocorticotrophin hormone (ACTH) in the anterior pituitary, which stimulates 
corticosteroid production in the adrenal glands.  
 Glucocorticoids (GC), such as cortisol, have extensively been studied in the 
context of distress and have previously been studied in EE. Distress is associated with a 
substantial increase in GC beyond the normal physiological range. EE on the other hand 
is associated with a mild increase in GC that is significant but within the physiological 
range. This finding supports the possibility that eustress, represented by EE, is an 
intermediate and healthy stressor state between lack of stimulation and distress.  
Furthermore, the large increase in GC in distress is associated with an 
immunosuppressive state, whereas the mild increase in GC in EE is actually associated 
with an increase in CD8 T-cells and natural killer (NK) cells. With regard to T-cell 
development, GC has previously been shown to promote positive selection of T-cells. 
To test the hypothesis that activation of the HPA axis mediates the EE thymic 
phenotypes, we obtained mice that had either undergone an adrenalectomy surgery or 
sham control surgery, and randomly assigned them to SE or EE housing for five weeks. 
After five weeks, we observed that sham EE-housed mice had an elevated serum 
corticosteroid level but no change in serum ACTH was observed, confirming that the 
adrenalectomy had prevented corticosteroid production and that the sham surgery had not 
prevented corticosteroid production (confirmatory data not shown). 
Adrenalectomy (ADX) eliminated the EE-induced reduction in thymus weight 
(Figure 12A). When we investigated the thymocyte populations, we observed that the 
EE-induced increase in CD8 T-cells observed in sham mice was eliminated in 
adrenalectomized-EE mice (Figure 12B and 12C). Overall, the data supports the 

























































To test whether the effects of corticosteroids directly regulated thymocyte 
development, we used a conditional knockout mouse train LCKCreGRlox (GRlck-Cre), in 
which the glucocorticoid receptor (GR) gene is deleted in the thymus in the DN4 stage 
(when LCK is expressed), such that DP, SP CD4, and SP CD8 cells lack responsiveness 
to glucocorticoids. When GRlck-Cre mice were housed in EE for five weeks, we observed 
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Figure	  12B.	  Thymus	  Phenotypes	  in	  ADX	  
Figure	  12C.	  
Figure	  13.	  GR-­‐LCK	  Mice	  
A	  
B	  
As may be expected from (1), we also tested the effect of ablation of SNS in 
thymocyte development. Upon ablation of SNS, all EE-associated thymocyte changes 
persisted (data not shown). This could indicate either that SNS has its effects on T-cells 
after export from the thymus or downstream of HPA axis. 
 
 
Intermediate Conclusion #2: Hypothalamic	  BDNF	  regulates	  thymocyte	  development	  




(3) IL-15 overexpression leads to decreased tumor mass 
 
 The Cao lab recently created an adeno-associated viral vector that travels 
specifically to adipose tissue. They have published its use in delivering a Cre 
recombinase to delete insulin receptor from mice with floxed insulin receptor.  
Other work between our groups has focused on the immune microenvironment in 
EE within adipose tissue of several depots. We have studied extensively cells of the 
innate immune system, specifically innate lymphoid cells. Innate lymphoid cells (ILCs) 
are a newly-classified cell in the innate immune system that includes natural killer cells 
as well as three distinct classes of ILCs that are involved in functions ranging from 
metabolism to helminth expulsion in the gut. (Our unpublished studies on ILCs and other 
immune cells in adipose tissue are not included here, as they do not directly relate to EE’s 
anticancer phenotype.) 
Our preliminary results in these studies have shown that EE increases NK cells in 
visceral adipose tissue. With the discovery of this adipose-specific vector, we wondered 
whether delivery of interleukin-15 (IL-15), which recruits NK cells, specifically to 
adipose tissue would increase NK cells in adipose tissue. Furthermore, we wanted to test 
whether this presumed increase in NK cells would lead to decreased tumor mass in the 
local area.  
 
Therefore, we hypothesized that vector-mediated, adipose-specific IL-15 
overexpression would lead to increased NK cells in adipose tissue and decreased 
local tumor growth. 
 
To test this hypothesis, we injected mice with AAV containing IL-15 
overexpression or scrambled sequence as control and subsequently injected with 
melanoma tumor on the flank. Three weeks later, mice were sacrificed and tumors were 
separated from surrounding tissue, measured for volume, weighed, and photographed. 
Tumors and adipose tissue were then processed for flow cytometry analysis.  
Tumor masses were significantly decreased in mice administered AAV containing 
IL-15 (Figure 14A and 14B). (One outlier in the IL-15 group increased p value.) NK cells 
were increased in the adipose tissue (data now shown), as expected in the IL-15 group. 
NK cells were also increased in the tumor (Figure 14C), suggesting some level of 





































Intermediate Conclusion #3: IL-15 overexpression in adipose tissue leads to increased 













































Figure	  14A.	  IL-­‐15	  Overexpression	  
Figure	  14B.	  
Figure	  14C.	  
(4) EE confers survival benefit in AML 
 
 Our lab has had a long-term focus on blood cancers, with much recent effort into 
acute myeloid leukemia (AML). While our previous studies of EE (and all others in the 
literature) have shown an anticancer effect in EE for solid tumor models, no studies have 
focused on blood cancers, such as AML, in EE.  
Therefore, we wanted to test whether EE improves disease outcomes for AML in 
mice, and we tentatively hypothesized that in an AML survival study mice living in 
EE would have a survival benefit over SE. 
 To test EE’s effect on AML, mice with CD45.1(+) immune cells were sublethally 
irradiated (400 Cgy) to partially destroy immune cells in the bone marrow. Six hours 
later, we transplanted MllPTD/WT:Flt3ITD/WT leukemia cells into these mice via tail injection 
at a dose of two million cells per mouse. (Two million cells from this mouse donor has 
previously shown a survival of around 30 days.) Mice were randomly assigned to either 
EE or SE housing following injection. 
 EE mice had a median survival that was 14% longer than SE mice (Figure 15A). 




















We also monitored AML progression through white blood cell (WBC) counts. At 
both 3 and 5 weeks, EE had significantly lower WBC counts (Figure 15B and 15C). 
Through video surveillance of mice, EE mice were drastically more active. Overall, these 
data suggest that EE substantially improves progression-free survival (the length of time 
in which the disease does not get worse), as evidenced by the differences in WBC counts 






















































Intermediate Conclusion #4: Enriched environment confers a modest, yet significant, 
























































For mouse experiments, male 3-week-old C57/BL6 mice were purchased from Charles 
River (Spencerville, OH) unless otherwise noted. We carried out all mouse experiments 





For enriched environment housing, mice are housed in 
cages 1.5 m x 1.5 m x 1.0 m with 10-20 mice per cage. 
Cages are supplemented with wheels, tunnels, igloos, 
huts, retreats, wood toys, a maze, and nesting material in 
addition to standard lab chow and water. An EE cage can 
be seen in Figure 16. Both EE and SE mice were housed 






Flow cytometry was used to identify populations of immune cells in a mixture via 
selective antibody staining. Shown below (Figure 16) is the antibody staining used to 
identify populations of T-cells, specifically CD4 and CD8 T-cells. In all panels, sytox 
was used to identify dead from live cells. Within the live cell fraction (sytox-negatice), 
the lymphocyte population was gated based on relative size and granularity standards. 
Doublets were excluded using a second size gating. For T-cells, all T-cells were defined 
as TCR-β positive, then further categorized as either CD4 or CD8 positive (with minor 
populations as either the double-negative or double positive in SLT). For thymocyte 
classification in the thymus, DN cells are in the lower left-hand quadrant of the CD4 




Melanoma Implantation and CD8 T-cell depletion 
 
The mouse B16-F10 melanoma cell line was purchased from ATCC (ATCC CRL-
6475TM) in 2014, and culture conditions followed ATCC’s instruction. The B16-F10 cell 
line was expanded in three passages, and the frozen stock was thawed and used for 
implantation in several experiments. For the CD8-depletion experiment, we housed mice 
in their respective environments for 5 weeks and then intraperitoneally injected 0.2 mg of 
anti-CD8 (BioXcell, clone YTS 169.4.2) or IgG (BioXcell) in 200 µL PBS. The day after 
antibody injection B16-F10 melanoma cells were subcutaneously implanted on the flank 
(1 x 105 cells/per mouse, n = 10 per group). The antibodies were injected once per week 
until sacrifice 18 days after melanoma implantation. The tumors were dissected away 
from neighboring tissues, measured for approximate volume, and weighed. 
 
rAAV Vector Construction and Packaging 
 
The recombinant adeno-associated virus (rAAV) plasmid contains a vector expression 
cassette consisting of the CMV enhancer and chicken β-actin (CBA) promoter, WPRE 
(posttranscriptional regulatory element of woodchuck hepatitis virus) sequence, and 
bovine growth hormone poly-A region flanked by AAV inverted terminal repeats. Human 
BDNF cDNA was inserted into the multiple cloning sites between the CBA promoter and 
WPRE sequence. EGFP (enhanced green fluorescent protein) was cloned into the rAAV 
plasmid as a control. rAAV serotype 1 vectors were packaged, purified and the vectors 
were adjusted to 2 x 1013 vg/ml in PBS for injection. 
 
rAAV-mediated BDNF overexpression in hypothalamus.  
C57BL/6 mice, male, 5 weeks of age, were randomly assigned to receive AAV-BDNF (n 
= 5–7) or AAV-GFP (n = 5). Mice were anaesthetized with ketamine/xylazine and 
secured via ear bars and incisor bar on a Kopf stereotaxic frame. A mid-line incision was 
made through the scalp to reveal the skull and two small holes were drilled into the skull 
with a dental drill above the injection sites (−1.2 AP, ± 0.5 ML, −6.2 DV, mm from 
bregma). rAAV vectors were injected bilaterally into the hypothalamus (0.5 µl per site) at 
a rate of 0.1 µL per minute using a 10 µL Hamilton syringe attached to Micro4 Micro 
Syringe Pump Controller (World Precision Instruments, Sarasota, FL). At the end of 
infusion, the syringe was slowly raised from the brain and the scalp was sutured. Animals 
were placed back into a clean cage and carefully monitored post-surgery until recovery 




AAV vectors containing microRNA targeting BDNF (miR-Bdnf) and the scramble 
control (miR-scr) were previously used in the Cao lab’s study of EE’s anticancer effect. 
We randomly assigned 6-week-old male C57BL/6 mice to receive AAV-miR-Bdnf (n = 
15) or AAV-miR-scr (n = 15). We injected 0.7 µL of AAV vectors (1.4 x 1010 per site) 
bilaterally into the hypothalamus at the stereotaxic coordinates described above. Seven 
days after surgery, each vector-injected group was split to live in enriched (n = 8 miR-
Bdnf, n = 8 miR-scr) or control housing (n = 7 miR-Bdnf, n = 7 miR-scr).  Mice were 








 Overall, our results have shown a substantial change in T-cell development, 
migration, and function in EE. Our preliminary data showed that CD8 T-cells are 
required for EE’s anticancer effect. Furthermore, we described a shift in T-cell 
populations within SLT toward CTLs. This shift in T-cell populations is early and 
consistent and is therefore likely to lead EE’s T-cell-mediated anticancer effect. 
Furthermore, through depletion and overexpression experiments, we showed that BDNF 
is a mediator of this T-cell change. Through blockade of both SNS and HPA axis, we 
further showed that both of these stress axes mediate EE’s T-cell change.  
 Since T-cells develop in the thymus, we hypothesized that EE exerts this T-cell 
phenotypic change in SLT through developmental shifts in the thymus. EE thymuses 
undergo thymic involution. Within the T-cell developmental pathway, there was a higher 
percentage of thymocytes in DN and CD8 stages and fewer in the DP population. This 
shift indicates pushing cells out of the intermediate double-positive stage toward CD8 
single positive cells, which could contribute to the SLT phenotype of a decreased 
CD4:CD8 ratio. Furthermore, we sought to connect the thymic developmental changes in 
EE with BDNF and potential SNS and HPA control. Through similar overexpression and 
depletion experiments of BDNF, we showed that BDNF mediates EE’s changes in T-cell 
populations in the developing thymus as well. Furthermore, we showed that HPA axis, 
and not SNS, controls the thymocyte shift. To more specifically test this connection, we 
used a mouse which deletes glucocorticoid receptor in all cells after the DN stage. There 
was no difference in EE thymocyte populations compared with SE, further confirming 
our hypothesis that EE works through HPA axis to mediate thymus changes.  
 Yet, CD8 T-cells are just one portion of the story. Our research into adipose tissue 
has shown us that EE confers a complex change in the immune microenvironment that is 
fat depot-specific. We have seen significant changes in innate immunity, notably an 
increase in NK cells. We hypothesized that recruitment of NK cells to adipose tissue 
could result in increased killing of tumor cells of a nearby tumor. To test this hypothesis 
we utilized the Cao lab’s recently developed adipose tissue-specific AAV vector. We 
inserted IL-15 into the vector, which resulted in recruitment of NK cells specifically to 
the tumor and decreased tumor mass, compared to control. 
 With these experiments on solid tumors, there is still much to do. Our preliminary 
results studying AML showed a slight increase in survival for mice housed in EE with a 
significant increase in progression-free survival. It is still unknown what causes this 
increase in progression-free survival but then a steady decrease in survival of EE mice. 
Furthermore, we do not yet know whether T-cells, NK cells, or, most likely, some 
combination of several immune cells coordinates the increase in progression-free 
survival.  
 This work, and this entire collaboration, shows the importance of a model of 
eustress in the study of cancer. While clinical studies have begun to study the positive 
effects of a supportive environment, laboratory and animal-model studies tend to focus 
on distress, such as social isolation, to see how these environments make cancer worse. 
Our model uniquely studies how cancer outcomes can be improved. EE is applicable to 
phenotypically diverse cancers, including both solid-tumor and blood cancers. 
Furthermore, our mechanistic studies create an opportunity for the manipulation of a 





 Cancer is a heavily studied, multifactorial disease with an incidence of nearly 1.7 
million in the U.S. alone. Recent clinical evidence suggests a positive effect of the social 
environment on cancer outcomes.Yet, animal model experiments have mainly focused on 
the negative effects of distress or social isolation on cancer outcomes. Our model of 
social enrichment, an enriched environment, is a model of eustress, and we uniquely 
study the positive effects of the social environment on cancer outcomes. We have 
previously shown that EE exerts an anticancer effect. Here, we show that CD8 T-cells at 
least partially mediate this response, though they are not the entire story of EE’s 
anticancer phenotype (Figure 3). Furthermore, we show a shift to CD8 T-cells in 
secondary lymphoid tissue that is mediated by a molecule in the hypothalamus, brain-
derived neurotrophic factor, which we had previously been shown to mediate EE’s 
anticancer effect in general.  
We then sought to understand the T-cell developmental changes that lead to the 
change in the CD4:CD8 ratio in SLT. We showed a shift in thymocyte development 
toward single-positive CD8 thymocytes in EE that is also regulated by BDNF. We show 
through a genetic knockout mouse that EE’s thymocyte development changes are 
mediated by the hypothalamic-pituitary-adrenal axis, specifically through binding of 
glucocorticoids to glucocorticoid receptor on developing thymocytes. 
We have further studied the complex effect of EE on the adipose tissue 
microenvironment, specifically on natural-killer cells. Here, we show that adipose tissue-
specific IL-15 overexpression results in increased NK cells in adipose tissue as well as 
increased NK cells at a nearby tumor and decreased mass of the nearby tumor.  
Finally, we extend the current knowledge of EE’s anticancer effect to a blood 
cancer, acute myeloid leukemia, in which we see a substantial increase in progression-
free survival but a modest, yet still significant, increase in overall survival.  
These results together show the complex connection between the environment, 
the nervous system, the immune system, and the cancer microenvironment in mice. The 
continual regulation of EE’s anticancer effect by BDNF suggests the possibility of 
manipulating a single gene in the brain for beneficial outcomes in certain cancers. Our 
model shows the importance of studying the positive effects of the environment on 
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